Nabi Biopharmaceuticals - SWOT Analysis

Datamonitor's Nabi Biopharmaceuticals *SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the companys key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Nabi Biopharmaceuticals (Nabi) is engaged in the development of products that target medical conditions in the areas of nicotine addiction and infectious diseases. The company has a product pipeline focused on significant market opportunities where current treatment options are inadequate, such as drug-resistant gram-positive infections and nicotine addiction. Nabi is headquartered in Rockville, Maryland and employs about 50 people. The company did not recorded revenues during the financial year (FY) ended December 2007, as it sold out its marketing products. The operating loss of the company during FY2007 was $44.9 million as compared to an operating loss of $61.3 million in 2006. The net profit was $47 million in FY 2007, as compared to a net loss of $58.7 million in 2006.

Scope of the Report

• Provides all the crucial company information required for business and competitor intelligence needs
• Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
• Data is supplemented with details on the companys history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement

Reasons to Purchase

• Support sales activities by understanding your customers businesses better

*Qualify prospective partners and suppliers

• Keep fully up to date on your competitors business structure, strategy and prospects
• Obtain the most up to date company information available

This report covers the following industry codes:

SIC Code: 2836

NAICS Code: 325414